Replay available

Acacia Research (NASDAQ:ACTG) Q4 2020 Earnings Call

Acacia Research (NASDAQ:ACTG) Q4 2020 earnings call, held 2021-03-29. Watch the replay and read the transcript on 6ix.

Mon, March 29, 2021 at 11:00 AMendedReplay
Acacia Research (NASDAQ:ACTG) Q4 2020 Earnings Call
Company
Acacia Research Corporation (NASDAQ:ACTG)
Period
Q4 2020 earnings call
Date
Mon, Mar 29, 2021, 11:00 AM ET
Replay
Watch the replay on this page · 28 min
Results news release
Acacia Research Reports Fourth Quarter and Full-Year 2020 Financial Results · Mon, Mar 29, 2021

On 6ix: 6ix.com/event/acacia-research-corporation-actg-q4-2020-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Greetings and welcome to the Acacia Research fourth quarter and full year results conference call. At this time, all participants are in a listen-only mode. The question and answer session will follow the formal presentation. If anyone wants to require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce Rob Fink of Investor Relations. Thank you. You may begin.

0:29 Thank you, Operator. Hosting the call today are Clifford Press, Acacia's Chief Executive Officer, Al Tobia, Chief Investment Officer, and Rich Rosenstein, Chief Financial Officer. Before beginning, I'd like to remind you that the information provided during this call may contain forward-looking statements relating to current expectations, estimates, forecasts, and projections about future events that are forward-looking as defined in the Private Securities Litigation Reform Act. of 1995. These forward-looking statements generally relate to the company's plans, objectives, and expectations for future operations and are based on the current estimates and projections, future results, or trends.

1:14 Actual results may differ materially from those projected as a result of certain risks and uncertainties. For a discussion of such risks and uncertainties, please see the risk factors described in Acacia's annual report on Form 10-K and quarterly reports on Porn10Q that are filed with the FCC. I would like to remind everyone that a press release disclosing the company's financial results was issued this morning before the market opened. This release may be accessed on the company's website at acaciaresearch.com under the news and events tab. With all that said, I'd now like to turn the call over to Clifford Press. Clifford, the call is yours.

1:54 Thank you, Rob, and good morning, everyone. This has been a year of significant transformation for Acacia. On the strength of an opportunistic life sciences transaction, we added $117.5 million or approximately $2 per share to our book value, an increase of 67%, and positioned the company for a wide range of value creation opportunities. We remain focused on executing Thank you very much. Thank you very much.

3:21 Thank you very much. As previously stated, our business is to acquire operating companies, divisions, or other assets where we believe we can realize significant value following an operational or strategic restructuring. Our primary focus is on companies operating in mature technology, healthcare, industrial, and certain financial services segments.

4:12 I'll now turn the call over to Al Tabea, our Chief Investment Officer.

4:19 Thank you, Clifford. As a reminder, in the second quarter, Acacia acquired 18 public and private life sciences companies for a total consideration of $282 million or 224 million pounds. This acquisition originated from our process of identifying and evaluating a potential acquisition candidate. To date, we have recovered approximately 189 million and hold public positions worth an additional 104.8 million and private positions worth approximately 162.5 million, representing holdings of 267.3 million. So this portfolio represents more than 450 million in cash and equity value on our balance sheet, which is a gain of approximately 60% over our initial investment.

5:17 Turning to our IP business, Subsequent to the end of the fourth quarter, we acquired a portfolio from Neurocom. This portfolio consists of a broad range of foundational Wi-Fi patents that cover various applications including mobile devices, wearables, digital home, home automation, healthcare, and industrial automation. Of particular importance during the year, we completed the build of our investment and operations team. This group consists of individuals with both public and private equity experience spanning our primary focus industries for targeting acquisitions. As part of this, we welcome Jason Soncini, our recently hired general counsel.

6:03 Our team is now at an appropriate scale to advance our acquisition strategy. With that, I would like to turn the call over to Rich Rosenstein, our CFO, to discuss the results. Rich?

6:17 Thank you, Al. Our book value at December 31st, 2020 was $292.5 million or $5.94 per basic share compared to $202 million or $4.17 per basic share at September 30th at $164.7 million or $3.36 per share at June 30th. It is important to note that this book value reflects the gap treatment of our non-cash warrant and embedded derivative liabilities. Given the volatility in our share price, those warrant and embedded derivative liabilities increased in value during the quarter and are now recorded on our balance sheet at an aggregate value of in excess of $59 million or $1.22 per share.

7:03 Those liabilities reflect the gap value of all warrants outstanding recognized as non-cash charges for potential issuance of shares. upon exercise and or expiration, these liabilities will be eliminated and reclassified to equity. For the quarter, our financial results included cash and short-term investments totaling $274.6 million at December 31st compared to $168.3 million at December 31st, 2019. Debt was $115 million in senior secured notes issued to Starboard, and in the fourth quarter we had revenue of $4.4 million. Let me spend a moment discussing our current capital structure. We currently have 49.2 million diluted shares outstanding.

7:52 Book value with December 31st, 2020 was $5.94 per share as I mentioned a moment ago. We have issued 115 million in notes to starboard value and we have 35 million in series A preferred shares outstanding. These notes and preferred shares can each be converted into common shares at $3.65 per share. If all of these notes and preferred shares were converted, it would add 41 million shares to our share count. The net result of this is we would have a total of 90 million shares. But we would eliminate 150 million in notes liability and preferred stock and the liabilities associated with those instruments. Additionally, Starboard holds additional warrants that, if exercised, would result in more cash coming into the company.

8:41 Let me break those down.

8:43 First, Starboard holds another 68.5 million Series B warrants that can be exercised at $5.25 per share, even if we never issued additional notes. Those expire in August of 2022. If exercised, That would add $360 million in cash and 68.5 million shares. Second, Starboard holds 5 million Series A warrants that are exercisable at $3.65 per share in cash. If exercised, these would add another $18 million in cash and 5 million shares. In aggregate, these would add an additional 73.5 million shares but bring in $378 million in cash. and more. Relative to our current book value and shares outstanding, we would have the following in total if all of these were exercised.

9:35 Diluted shares outstanding of 163 million shares comprised of our current 49 million diluted shares plus 41 million shares from existing notes and preferred plus 73.5 million from the remaining warrants. Under this scenario, if all of these instruments were exercised, Our book value would increase by 590 million, which includes the following. First, 378 million in additional cash. Second, a reduction in notes liabilities and preferred stock of 150 million. And third, the elimination of 62 million of warrant and other derivative liabilities associated with these notes and preferred stock. In aggregate, the impact of exercise of all of these warrants and conversion of the preferred would result in a book value per share of $5.39 versus $5.94 on an undiluted basis.

10:30 One last point. While this analysis discusses the impact of potential exercise by Starboard Value of all of its warrants and preferred stock, it is important to remember that consistent with our net operating loss preservation policies, the terms of the preferred stock and warrants prevent Starboard Value from converting or exercising such securities to the extent such conversion or exercise would cause Starboard Value, together with its affiliates, to beneficially own in excess of 4.89% of the company's outstanding shares of common stock following such conversion or exercise. More detail on these results have been made available on the press release issued this morning and also in the upcoming annual report on Form 10-K, which we will file with the SEC later today. Let me now turn the call back to Clifford for closing comments.

11:18 Clifford?

11:20 Thanks, Rich. In conclusion, Acacia continues to execute on its investment strategy. As always, our focus continues to be on improvement in our book value and a strong balance sheet with which we can make additional investments. Our flexibility remains a key asset in today's economy. Together with Starboard, We are well positioned to pursue strategic transactions of greater scale and flexibility. We are now happy to answer questions. Operator? Thank you. We will now be conducting a question and answer session. If you would like to ask a question, please press star 1 on your telephone keypad.

12:05 A confirmation tone will indicate your line is in the question queue. You may press star 2 if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the start keys. One moment, please, while we poll for your questions. Our first questions come from the line of Anthony Stoss with Craig Hallam. Please proceed with your questions.

12:36 Good morning, guys. I think I have three questions in total.

12:40 and maybe this is for Rich.

12:41 Rich, can you lay out what the book value would be as of maybe the close of Friday with public securities, et cetera, both on a basic share basis and on a fully diluted basis? And then I guess maybe for Clifford, any thoughts on the Oxford Nanopore potential filing for an IPO, what you've heard or any thoughts on the timeline on that? And then lastly, if somebody wants to field this one as well, may be more difficult to talk about, but any update on where you stand with Starboard in terms of finding a operating business acquisition? Thanks.

13:16 Rich, do you want to answer the first part of that question and then I'll answer the other two?

13:22 Sure. So the only change since 1231 would be the change in stock price for ARIC, Sensime, and and Immunicor, which is now trading publicly. So I'd have to look at precisely how much that's increased in value. But Immunicor alone has increased in value since 1231 by approximately 32 million. And Sensine and ARICS, I would need to check, call it in total about 40 million higher. So on our current share count, that will be another and more.

14:14 With regard to Nanopore, that's a very dynamic company with a lot of options available to it. We are extremely supportive shareholders and we will see what they decide to do. but they have a lot of options and I don't know anything more than that. With regard to potential transactions with Starboard, there's a range of things that we're looking at. The particular type of transaction we would like to do is going to probably be illustrated when we do one which I hope to do shortly and then I think that will clarify what we're looking at.

15:01 Thank you. Thank you. Our next questions come from the line of Brett Reese with Jannie Montgomery Scott. Please proceed with your questions.

15:12 Morning, gentlemen. Thanks for a well-crafted press release with all the information. Good job on that. I guess the first question, until you run through the tax loss carry forward starboard so that you don't jeopardize the net operating loss carry forward will not convert the notes and preferred into common for the time being?

15:56 Yes, Brandon. These documents are public. and so they're available for people to see. But the restriction on Starboard's conversion is in the documents.

16:13 Okay.

16:15 And thank you for your compliment on the press release. We've had very explicit requests from you and others on a number of these subjects and we tried to make sure that it was all in there.

16:27 Yes, good show on that. And just on the 68.5 million warrants at five and a quarter, I thought in the past for Starboard to be entitled to that, they would have had to provide the additional 350 million or so in stopgap financing. Is that still the case or not? I'm a little unclear on that.

17:06 I'll take that. These warrants are exercisable in two ways. One is if we issue notes and Starboard were to finance an approved transaction, an approved investment that we would do, then those notes could be exchangeable through the warrants into equity at 365 a share. If we do not issue those notes, those warrants still have an exercise feature at $5.25 a share, independent of any note issuance, and that feature is available until August 2022. So up until August 2022, if we haven't issued any additional notes, Starboard could exercise those 68.5 million warrants for 525 in cash, which would be the 360 million in cash that will come into the company.

18:02 Okay. I appreciate that. You know, with all of the SPAC issuance, I mean, there are just so many competitors in the market looking for the operating company that you're looking for. Suppose in a year or so you can't find something, with all of the available cash, would you get more aggressive in the patent intake portfolio business? Would you consider declaring a special dividend? What happens if we can't find an operating company at a decent price?

18:50 Well, that's a highly hypothetical question. I think so far we've shown that we are able to find assets that have good value. We do not intend to change that approach now. We will not be relaxing our discipline on these things. But I also think that with the mandate that we have, it's very, very different than SPACs and these other assets. Vehicles that are out there. The specs cannot buy public companies. We have a whole range of transactions we can do. I would say, Brett, I think it's highly unlikely that the time will come a year from now where we haven't found constructive ways to invest our capital.

19:40 Okay. Thank you for taking my questions. I'll drop back. Thank you. Thank you. Our next questions come from the line of Dominic Marshall with Pacific Ridge Capital. Please proceed with your questions.

19:58 Good morning. Just, you know, most of my questions have already been asked, but wanted to follow up kind of on the last ones. Just, I guess, ask a little bit different way. I was hoping you could kind of just talk about, you know, to the extent that you can, what you're seeing, you know, both on the operating company front, you know, what is your, you know, due diligence pipeline look like there? Obviously, we all know what's happening with valuations. But as you just got done describing, you know, you guys are maybe looking at a little different space. But if you kind of just talk about where you're at on that front. And then secondly, on the IP business, hoping you could just maybe give a little bit more color there kind of what your expectations are for, you know, intake and then, you know, with what you already have over the course of the next year or two, just a little more detail on on that side of the business.

20:50 Thanks, Dominic. So I'll take the beginning of the question and then Rich can talk a little bit about the IP business. What I would say is that we've always looked at this as a market when we're doing our research to look at public companies in the whatever you want to call micro cap range. So we've said at times sub 2 billion, it's probably going to be more like sub 1 billion. We've seen often when companies come public, there's a pressure on them to grow revenue, and oftentimes you find companies that have been public for a while that maybe hit the gas too much on the inorganic growth versus actually the return on equity side.

21:40 Often we find that this theme continues in all markets, up, down, and sideways, but it just depends on which sector you're looking at. Back to Clifford's point before versus SPACs, our mandate is to try to operate at the intersection of public and private equity and use an array of instruments, whether it's looking at the division of a company, whether it's recapitalization of a balance sheet, or just a straight-up take-private. and so those are the kind of tools we're looking at in terms of utilizing them and we will see opportunities in all markets. We just have to look in different sectors and different areas but we'll stay focused on that sort of micro cap public marketplace.

22:34 Dominic, I'll add a little bit to what Al has described there. One thing is, as I said earlier, it's a difficult type of transaction to describe Thank you very much. We still have a lot that we're working on, and it'll, I think, speak for itself when it comes out. I think the point that Al made is we're very different than a SPAC, we're very different than a lot of other entities out there, and we intend to prove that out.

23:31 Thank you. That's helpful. Before you move on to the IP question, just following up on that a little bit more, I think you used the term there, acquisitions, so that kind of goes to my other question, which is, Al, you talk about the high end, maybe a billion or two billion, but I guess how small are you willing to go and how many companies might you be willing to go after on the operating front? If multiple is the answer, how many small deals might you potentially do and over what time frame? Obviously, you don't have an exact answer, but if you can kind of just ballpark it a little bit.

24:11 So, you know, you want to obviously maximize your opportunities and also be efficient, right? We don't want to do a lot of tiny deals. And what I mean by tiny, you know, we're looking at probably on the low end, you're talking about 100 to 200 million would be a small deal. And I think the sweet spot is probably five to 600 million is sort of where we would, I think, like to operate. I think that's where we'll probably see the most and many more. We're looking at utilizing our overhead as efficiently as possible.

25:15 Sounds good. That makes sense. Given that sweet spot size then, it sounds like one or two over the course of the next year or two is probably more likely than a number much bigger than that.

25:26 Yes, I'll tell you that's where our incentive comp parameters have been drawn by the board in that type of range. And just to answer your question on the IP environment, That's been very interesting. You may recall when we first became involved here, we said that the IP business appeared to have gone through essentially a distressed business with very little capital being provided and had gone through a period of declining outcomes. That has gone 100%, 180 degrees the other way. There have been some astounding IP businesses Settlements and judgments recently that have been upheld. I'd say that it's almost transformed in terms of the outlook.

26:20 Our group seems to be doing a very good job with the wind in their sails, and I think we'll see some interesting opportunities there.

26:34 Great. Well, certainly would love more detail, but I appreciate that and appreciate all your answers. Thank you. Our next question has come from the line of Calvary Levitt with Anhinga Investment Partners. Please proceed with your questions. Hi. Thank you for taking the question.

26:54 The Starboard deal had a rights offering component in it.

26:58 I just wanted to hear thoughts from you guys on any potential timing of a rights offering. Thanks.

27:05 Thank you very much. We very much look forward to distributing those rights and giving existing Acacia shareholders an opportunity to invest in the transaction on exactly the same terms as Styleboard.

27:40 Thank you very much.

27:47 Thank you. There are no further questions at this time. We appreciate your participation. This does conclude today's teleconference. You may disconnect your lines at this time.

27:58 Have a great day.

Follow Acacia Research Corporation into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Clifford Press

Chief Executive Officer

Rich Rosenstein

Chief Financial Officer

Rob Fink

Head of Investor Relations

Al Tobia

Chief Investment Officer

Anthony Stoss

Analyst, Craig Hallum Capital

Brett Reese

Analyst, Janney Montgomery Scott

Dominic Marshall

Analyst, Pacific Ridge Capital

More from Acacia Research Corporation